Biocon Ltd

Go Back

Biocon Ltd

  • Ranked 1st in the Glargine vial market
  • Ranked 1st among Indian Insulin companies
  • Among the world’s largest producers of statins and immunosuppressants
  • As of September 2014, total assets stood at Rs 2,525.1 crore (US$ 407.24 million)

Biocon Ltd is India's largest biotech company delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.

Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. The growth of the company is fuelled by five powerful accelerators including small molecules, biosimilars, branded formulations, novel molecules, and research services with a focus on emerging markets.


Biocon Ltd: An early mover in the global biotech market

2014 Biocon has been conferred with the Sir J C Bose Memorial Award – 2013 (Institutional category) by Indian Science Monitor (ISM).
2011 Biocon announced project commencement for first high-end biopharmaceutical manufacturing and R&D facility in Bio-XCell, Malaysia.
2006 Biocon inaugurates Biocon Biopharmaceuticals, India's largest multi-product Biologics facility at Biocon Park.
2000 Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals.
1979 Biocon is the first Indian company to manufacture and export enzymes to USA and Europe.

Updated: January, 2015

Science and R&D
India ranked 13th in Nature Index 2017 based high quality research in natural sciences.